TrueBinding

TrueBinding Inc. is a clinical-stage biotherapeutic company developing novel monoclonal antibody therapeutics for neurodegenerative and metabolic diseases, stroke, oncology, and other areas with significant unmet medical needs. Their lead candidate, TB006, is a humanized monoclonal antibody targeting Galectin-3, currently under investigation for potential disease-modifying effects in Alzheimer’s and Parkinson’s diseases.